SARS1

SARS1 (seryl-tRNA synthetase 1) is a cytosolic aminoacyl-tRNA synthetase that ligates serine to its cognate tRNA, an essential step in protein synthesis whose loss is incompatible with normal cellular maintenance (PMID:36041817). Direct serylation assays in patient fibroblasts and yeast complementation establish that disease-associated SARS1 variants impair aminoacylation activity, and loss of function drives cellular senescence marked by arrested division, beta-galactosidase accumulation, and elevated SASP factors (IL-6, p21, p16, p53) (PMID:36041817). A recurrent biallelic active-site missense variant (p.Arg213Leu) destabilizes the protein and reduces enzymatic activity, causing a neurodevelopmental syndrome with developmental delay, deafness, cardiomyopathy, and metabolic decompensation (PMID:34570399); SARS1 variants are thus causative of recessive and dominant-negative neurodevelopmental disorders (PMID:36041817, PMID:34570399). Beyond catalysis, SARS1 coordinates tRNA modification through interaction with m3C32 tRNA methyltransferases and exerts non-canonical nuclear functions, including repression of VEGFA transcription in complexes with YY1 and SIRT2 and binding of telomeric DNA in cooperation with POT1 to regulate telomere length, with these activities tuned by hypoxia-driven phosphorylation and nutrient-dependent glycosylation (PMID:38255739). SARS1 is a pan-essential dependency that can be selectively degraded in HPV-positive cancer cells (PMID:40049166).

1. 2021 Medium

   Establishing whether a recurrent SARS1 active-site variant is biochemically deleterious connected the gene to a defined neurodevelopmental syndrome and showed the mechanism is protein destabilization plus catalytic loss, not merely sequence change.

   Evidence Protein stability assessment and aminoacylation activity assay in patient-derived cells with clinical genetics

   PMID:34570399

   Open questions at the time

   • Did not test rescue/complementation to formally prove causality
   • Mechanism by which the variant destabilizes the protein not structurally resolved
   • Tissue-specific basis of the syndrome (deafness, cardiomyopathy) not addressed
2. 2022 Low

   Mapping a biallelic missense variant to the active site and linking biallelic SARS1 to microcephaly and brain anomalies extended the disease phenotype but rested only on structural inference of activity loss.

   Evidence Structural mapping of the variant onto SARS1 structure with biallelic-variant clinical genetics

   PMID:35790048

   Open questions at the time

   • No in vitro enzymatic assay reported to confirm the predicted activity reduction
   • Single lab, no functional rescue
   • Genotype-phenotype correlation across SARS1 patients not unified
3. 2022 High

   Direct serylation and yeast complementation assays proved that a SARS1 splice variant causes loss of function with a dominant-negative effect and, critically, that this loss drives cellular senescence — connecting tRNA charging deficiency to a defined cellular phenotype.

   Evidence Yeast complementation, serylation assays in yeast and patient fibroblasts, beta-galactosidase staining, morphology, and SASP marker measurement

   PMID:36041817

   Open questions at the time

   • Molecular route from aminoacylation loss to senescence induction not delineated
   • Whether dominant-negative action reflects subunit poisoning not directly shown
   • In vivo organismal phenotype not modeled
4. 2024 Medium

   Synthesis of prior primary data positioned SARS1 as a moonlighting protein beyond translation — coordinating tRNA modification, repressing VEGFA transcription in the nucleus, and binding telomeric DNA — defining a regulatory dimension to its biology.

   Evidence Review consolidating co-IP, nuclear localization, ChIP, post-translational modification, and interaction assays from prior studies

   PMID:38255739

   Open questions at the time

   • Corpus contains only the review abstract, not the underlying primary datasets
   • Signals controlling nuclear translocation versus cytosolic catalysis not fully mapped
   • Functional contribution of telomeric/VEGFA roles to the disease phenotype unestablished
5. 2025 Low

   Demonstrating that SARS1 is a pan-essential protein degradable via the HPV E6 E3 ligase showed it can be exploited as a selective vulnerability in virus-positive cancer cells.

   Evidence VIPER-TAC targeted degradation in HPV-positive cervical cancer cells with viability readout

   PMID:40049166

   Open questions at the time

   • Proof-of-concept degradation only; does not characterize SARS1's own catalytic mechanism
   • Selectivity and off-target effects in non-cancer cells not detailed
   • Single-lab study

• How SARS1's non-canonical nuclear and telomeric functions are mechanistically coupled to — or separable from — its essential aminoacylation activity, and how each contributes to senescence and neurodevelopmental disease, remains unresolved.
• No structural model linking active-site variants to dominant-negative subunit behavior
• Direct primary evidence for VEGFA/telomere roles absent from this corpus
• Causal chain from charging defect to senescence and tissue pathology undefined